The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use-Reference-Cited by-同舟云学术

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use

Published:2013-03 Issue:3 Volume:24 Page:618-624
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Eiermann W.,Rezai M.,Kümmel S.,Kühn T.,Warm M.,Friedrichs K.,Schneeweiss A.,Markmann S.,Eggemann H.,Hilfrich J.,Jackisch C.,Witzel I.,Eidtmann H.,Bachinger A.,Hell S.,Blohmer J.

Funder

Genomic Health Inc

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/3/618/538948/mds512.pdf

Reference35 articles.

1. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009;Goldhirsch;Ann Oncol,2009

2. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer;Paik;N Engl J Med,2004

3. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer;Paik;J Clin Oncol,2006